Market by Type (Expanded Polytetrafluoroethylene (ePTFE), Polyurethane, Polyethylene Terephthalate (PET), Other Types) Blood Vessel Diameter (Large , Medium, Small) Patient Demographic (Adult, Pediatric) Application (Aortic Disease, Peripheral Artery, Hemodialysis) End-User (Hospital, Specialty Clinics, Ambulatory Surgical Center, Other End-User) and Country Outlook | Forecast 2024-2032
Triton Market Research’s report states that the Europe artificial blood vessels market is estimated to advance at a CAGR of 6.01% during the forecast period 2024-2032.
​​Report scope can be customized per your requirements - Request Free Sample Report
Growing investments in healthcare infrastructure and research by both governments and private sectors in Europe are accelerating the advancement and commercialization of innovative medical solutions, such as artificial blood vessels. The presence of skilled healthcare professionals and specialized treatment centers ensures the successful application of artificial blood vessel therapies. Additionally, supportive reimbursement policies in some European countries make these advanced treatments more accessible to patients.
The countries mentioned in this region include:Â
Germany leads the regional market, acquiring around $239.90 million in 2023
Germany is at the forefront of bioengineering, with projects like the development of 3D bioprinted blood vessels. The University Medical Center Schleswig-Holstein (UKSH), in collaboration with Kiel and Hamburg universities, is working on a prototype to create blood vessels using a patient’s cells. This can address the challenge of sourcing suitable blood vessels for bypass surgeries, a significant application of artificial blood vessels in the treatment of cardiovascular diseases.Â
The government is actively investing in medical technologies, particularly in areas like regenerative medicine. Initiatives through the Federal Ministry of Health and collaborations with research institutes like Fraunhofer are fostering technological advancements.Â
These efforts are part of Germany’s broader healthcare innovation strategy, which emphasizes sustainable medical solutions and cutting-edge surgical technologies.
Market Forecast for the United KingdomÂ
The artificial blood vessels market in the UK is advancing with promising innovations and government support, particularly in cardiovascular treatments. Leading research institutions like the University of Edinburgh have been at the forefront, developing 3D-printed artificial blood vessels that mimic human veins. In addition, the UK has made substantial investments in healthcare innovation, with around £30 million fund dedicated to improving NHS technologies. This includes advancements in 3D printing and diagnostics, which are crucial for enhancing treatments involving artificial blood vessels​.Â
The market is sectioned into patient demographics, type, blood vessel diameter, application, and end-user. The patient demographic segment includes adult and pediatric.
The adult population requiring cardiovascular implants consists of patients aged 19 and above. These individuals may need artificial blood vessel grafts due to conditions such as atherosclerosis (plaque buildup in arteries), congenital defects, trauma, or other health issues. Common conditions necessitating grafts include peripheral artery disease, coronary artery disease, aortic aneurysms, and the need for vascular access in hemodialysis. To improve graft performance, manufacturers employ techniques such as reinforcing the graft with layers or rings to prevent collapse or kinking.
Contender Analysis in the Artificial Blood Vessels Market:
Getinge AB, a Swedish company based in Göteborg, specializes in providing healthcare and life sciences solutions. Its product range includes surgical workspaces, intensive care units, sterilization systems, and life science production tools. With a global presence, Getinge serves clients worldwide through its sales and service networks, focusing on acute care therapies, surgical workflows, and life science systems.
The company’s line of products consists of Intergard Woven, a collagen-coated polyester graft with an external velour surface and a non-velour inner surface.Â
Other major firms include Roumai Medical, Vascular Graft Solutions, MedicalExpo, and Jiangsu Bioda Life Science Co Ltd.Â
KEY DELIVERABLES OF THE REPORT:
Market CAGR during the forecasting years 2024-2032
Detailed data highlighting key insights, industry components, and market strategies
Comprehensive information and estimation of the artificial blood vessels market revenue growth in Europe and its influence on the parent market
In-depth study of forthcoming trends in consumer behavioral patterns
A meticulous analysis of the competitive landscape and Porter’s Five Forces
A wide-ranging study of factors that will challenge the Europe artificial blood vessels market’s growth during the upcoming years
Want to get specific insights? Our team of analysts can customize this report based on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. EUROPE ARTIFICIAL BLOOD VESSELS MARKET –
SUMMARY
2. INDUSTRY OUTLOOK
2.1. PORTER’S FIVE FORCES ANALYSIS
2.1.1. THREAT OF NEW ENTRANTS
2.1.2. THREAT OF SUBSTITUTES
2.1.3. BARGAINING POWER OF BUYERS
2.1.4. BARGAINING POWER OF SUPPLIERS
2.1.5. THREAT OF COMPETITIVE RIVALRY
2.2. MARKET MATURITY ANALYSIS
2.3. SUPPLY CHAIN ANALYSIS
2.3.1. RAW MATERIALS
2.3.2. MANUFACTURERS
2.3.3. DISTRIBUTORS
2.3.4. END USER
2.4. REGULATORY FRAMEWORK
2.5. KEY BUYING IMPACT ANALYSIS
2.5.1. BIOCOMPATIBILITY
2.5.2. DURABILITY AND LONGEVITY
2.5.3. CUSTOMIZATION AND VERSATILITY
2.5.4. REGULATORY COMPLIANCE AND QUALITY ASSURANCE
2.6. KEY MARKET STRATEGIES
2.6.1. COLLABORATIONS
2.6.2. PRODUCT LAUNCHES
2.6.3. ACQUISITIONS
2.6.4. BUSINESS DIVESTITURES & EXPANSIONS
2.7. MARKET DRIVERS
2.7.1. RISING RATES OF CARDIOVASCULAR DISEASES AND
VASCULAR DISORDERS
2.7.2. DEVELOPMENTS IN TISSUE ENGINEERING AND
REGENERATIVE MEDICINE
2.7.3. AGING POPULATION AND SHIFTING LIFESTYLES
2.8. MARKET CHALLENGES
2.8.1. EXPENSES IN THE DEVELOPMENT AND
COMMERCIALIZATION OF ARTIFICIAL BLOOD VESSELS
2.8.2. STRICT REGULATORY APPROVALS AND CLINICAL
TRIAL REQUIREMENTS
2.8.3. CHALLENGES RELATED TO BIOCOMPATIBILITY AND
LONG-TERM DURABILITY
2.9. MARKET OPPORTUNITIES
2.9.1. ADVANCEMENTS IN 3D BIOPRINTING FOR TAILORED
VASCULAR GRAFTS
2.9.2. USE OF NANOTECHNOLOGY AND BIOMIMETIC
MATERIALS TO ENHANCE FUNCTIONALITY
2.10. ANALYST PERSPECTIVE
3. EUROPE ARTIFICIAL BLOOD VESSELS MARKET – BY TYPE
3.1. EXPANDED POLYTETRAFLUOROETHYLENE (EPTFE)
3.2. POLYETHYLENE TEREPHTHALATE (PET)
3.3. POLYURETHANE
3.4. OTHER TYPES
4. EUROPE ARTIFICIAL BLOOD VESSELS MARKET – BY BLOOD
VESSEL DIAMETER
4.1. LARGE
4.2. MEDIUM
4.3. SMALL
5. EUROPE ARTIFICIAL BLOOD VESSELS MARKET – BY
PATIENT DEMOGRAPHIC
5.1. PEDIATRIC
5.2. ADULT
6. EUROPE ARTIFICIAL BLOOD VESSELS MARKET – BY APPLICATION
6.1. PERIPHERAL ARTERY
6.2. HEMODIALYSIS
6.3. AORTIC DISEASE
7. EUROPE ARTIFICIAL BLOOD VESSELS MARKET – BY END-USER
7.1. HOSPITAL
7.2. SPECIALTY CLINIC
7.3. AMBULATORY SURGICAL CENTER
7.4. OTHER END-USER
8. EUROPE ARTIFICIAL BLOOD VESSELS MARKET – BY COUNTRY
OUTLOOK
8.1. EUROPE
8.1.1. UNITED KINGDOM
8.1.1.1. UNITED KINGDOM ARTIFICIAL
BLOOD VESSELS MARKET FORECAST & PROSPECTS
8.1.2. GERMANY
8.1.2.1. GERMANY ARTIFICIAL BLOOD
VESSELS MARKET FORECAST & PROSPECTS
8.1.3. FRANCE
8.1.3.1. FRANCE ARTIFICIAL BLOOD
VESSELS MARKET FORECAST & PROSPECTS
8.1.4. SPAIN
8.1.4.1. SPAIN ARTIFICIAL BLOOD
VESSELS MARKET FORECAST & PROSPECTS
8.1.5. ITALY
8.1.5.1. ITALY ARTIFICIAL BLOOD
VESSELS MARKET FORECAST & PROSPECTS
8.1.6. POLAND
8.1.6.1. POLAND ARTIFICIAL BLOOD
VESSELS MARKET FORECAST & PROSPECTS
8.1.7. REST OF EUROPE
8.1.7.1. REST OF EUROPE ARTIFICIAL
BLOOD VESSELS MARKET FORECAST & PROSPECTS
9. COMPETITIVE LANDSCAPE
9.1. BECTON, DICKINSON AND COMPANY
9.1.1. OVERVIEW
9.1.2. PORTFOLIO
9.1.3. KEY STRENGTHS
9.1.4. KEY CHALLENGE
9.2. LEMAITRE VASCULAR INC
9.2.1. OVERVIEW
9.2.2. PORTFOLIO
9.2.3. KEY STRENGTHS
9.2.4. KEY CHALLENGE
9.3. MEDTRONIC PLC
9.3.1. OVERVIEW
9.3.2. PORTFOLIO
9.3.3. KEY STRENGTH
9.3.4. KEY CHALLENGE
9.4. TERUMO MEDICAL CORPORATION
9.4.1. OVERVIEW
9.4.2. PORTFOLIO
9.4.3. KEY STRENGTHS
9.4.4. KEY CHALLENGE
9.5. W. L. GORE AND ASSOCIATES INC
9.5.1. OVERVIEW
9.5.2. PORTFOLIO
9.5.3. KEY STRENGTHS
9.5.4. KEY CHALLENGES
9.6. GETINGE AB
9.6.1. OVERVIEW
9.6.2. PORTFOLIO
9.6.3. KEY STRENGTHS
9.6.4. KEY CHALLENGE
9.7. ROUMAI MEDICAL
9.7.1. OVERVIEW
9.7.2. PORTFOLIO
9.7.3. KEY STRENGTHS
9.7.4. KEY CHALLENGES
9.8. MEDICALEXPO
9.8.1. OVERVIEW
9.8.2. PORTFOLIO
9.8.3. KEY STRENGTHS
9.8.4. KEY CHALLENGES
9.9. VASCULAR GRAFT SOLUTIONS
9.9.1. OVERVIEW
9.9.2. PORTFOLIO
9.9.3. KEY STRENGTHS
9.9.4. KEY CHALLENGES
9.10. JIANGSU BIODA LIFE SCIENCE CO LTD
9.10.1. OVERVIEW
9.10.2. PORTFOLIO
9.10.3. KEY STRENGTHS
9.10.4. KEY CHALLENGE
10. RESEARCH METHODOLOGY & SCOPE
10.1. RESEARCH SCOPE & DELIVERABLES
10.2. SOURCES OF DATA
10.3. RESEARCH METHODOLOGY
TABLE 1: EUROPE ARTIFICIAL BLOOD VESSELS MARKET, BY COUNTRY OUTLOOK,
2024-2032 (IN $ MILLION)
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: LIST OF COLLABORATIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF ACQUISITIONS
TABLE 6: LIST OF BUSINESS DIVESTITURES & EXPANSIONS
TABLE 7: EUROPE ARTIFICIAL BLOOD VESSELS MARKET, BY TYPE, 2024-2032 (IN
$ MILLION)
TABLE 8: EUROPE ARTIFICIAL BLOOD VESSELS MARKET, BY BLOOD VESSEL
DIAMETER, 2024-2032 (IN $ MILLION)
TABLE 9: EUROPE ARTIFICIAL BLOOD VESSELS MARKET, BY PATIENT
DEMOGRAPHICS, 2024-2032 (IN $ MILLION)
TABLE 10: EUROPE ARTIFICIAL BLOOD VESSELS MARKET, BY APPLICATION,
2024-2032 (IN $ MILLION)
TABLE 11: EUROPE ARTIFICIAL BLOOD VESSELS MARKET, BY END-USER, 2024-2032
(IN $ MILLION)
TABLE 12: EUROPE ARTIFICIAL BLOOD VESSELS MARKET, BY COUNTRY OUTLOOK,
2024-2032 (IN $ MILLION)
FIGURE 1: MARKET
MATURITY ANALYSIS
FIGURE 2: SUPPLY CHAIN
ANALYSIS
FIGURE 3: KEY BUYING IMPACT
ANALYSIS
FIGURE 4: EUROPE
ARTIFICIAL BLOOD VESSELS MARKET, BY TYPE, 2023 & 2032 (IN %)
FIGURE 5: EUROPE
ARTIFICIAL BLOOD VESSELS MARKET, BY EXPANDED POLYTETRAFLUOROETHYLENE (EPTFE),
2024-2032 (IN $ MILLION)
FIGURE 6: EUROPE
ARTIFICIAL BLOOD VESSELS MARKET, BY POLYETHYLENE TEREPHTHALATE (PET), 2024-2032
(IN $ MILLION)
FIGURE 7: EUROPE
ARTIFICIAL BLOOD VESSELS MARKET, BY POLYURETHANE, 2024-2032 (IN $ MILLION)
FIGURE 8: EUROPE
ARTIFICIAL BLOOD VESSELS MARKET, BY OTHER TYPES, 2024-2032 (IN $ MILLION)
FIGURE 9: EUROPE
ARTIFICIAL BLOOD VESSELS MARKET, BY BLOOD VESSEL DIAMETER, 2023 & 2032 (IN
%)
FIGURE 10: EUROPE
ARTIFICIAL BLOOD VESSELS MARKET, BY LARGE, 2024-2032 (IN $ MILLION)
FIGURE 11: EUROPE
ARTIFICIAL BLOOD VESSELS MARKET, BY MEDIUM, 2024-2032 (IN $ MILLION)
FIGURE 12: EUROPE
ARTIFICIAL BLOOD VESSELS MARKET, BY SMALL, 2024-2032 (IN $ MILLION)
FIGURE 13: EUROPE
ARTIFICIAL BLOOD VESSELS MARKET, BY PATIENT DEMOGRAPHICS, 2023 & 2032 (IN
%)
FIGURE 14: EUROPE
ARTIFICIAL BLOOD VESSELS MARKET, BY PEDIATRIC, 2024-2032 (IN $ MILLION)
FIGURE 15: EUROPE
ARTIFICIAL BLOOD VESSELS MARKET, BY ADULT, 2024-2032 (IN $ MILLION)
FIGURE 16: EUROPE
ARTIFICIAL BLOOD VESSELS MARKET, BY APPLICATION, 2023 & 2032 (IN %)
FIGURE 17: EUROPE
ARTIFICIAL BLOOD VESSELS MARKET, BY PERIPHERAL ARTERY, 2024-2032 (IN $ MILLION)
FIGURE 18: EUROPE
ARTIFICIAL BLOOD VESSELS MARKET, BY HEMODIALYSIS, 2024-2032 (IN $ MILLION)
FIGURE 19: EUROPE
ARTIFICIAL BLOOD VESSELS MARKET, BY AORTIC DISEASE, 2024-2032 (IN $ MILLION)
FIGURE 20: EUROPE
ARTIFICIAL BLOOD VESSELS MARKET, BY END-USER, 2023 & 2032 (IN %)
FIGURE 21: EUROPE
ARTIFICIAL BLOOD VESSELS MARKET, BY HOSPITAL, 2024-2032 (IN $ MILLION)
FIGURE 22: EUROPE
ARTIFICIAL BLOOD VESSELS MARKET, BY SPECIALTY CLINIC, 2024-2032 (IN $ MILLION)
FIGURE 23: EUROPE
ARTIFICIAL BLOOD VESSELS MARKET, BY ONLINE PHARMACY, 2024-2032 (IN $ MILLION)
FIGURE 24: EUROPE
ARTIFICIAL BLOOD VESSELS MARKET, BY OTHER END-USERS, 2024-2032 (IN $ MILLION)
FIGURE 25: EUROPE
ARTIFICIAL BLOOD VESSELS MARKET, BY COUNTRY OUTLOOK, 2023 & 2032 (IN %)
FIGURE 26: UNITED
KINGDOM ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $ MILLION)
FIGURE 27: GERMANY
ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $ MILLION)
FIGURE 28: FRANCE
ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $ MILLION)
FIGURE 29: SPAIN
ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $ MILLION)
FIGURE 30: ITALY
ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $ MILLION)
FIGURE 31: POLAND
ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $ MILLION)
FIGURE 32: REST OF
EUROPE ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $ MILLION)